Gain Therapeutics held its 2026 annual meeting of stockholders on June 24, 2026. Stockholders elected seven directors: Gene Mack, Dov Goldstein, M.D., Hans Peter Hasler, Khalid Islam, Ph.D., Gwen Melincoff, Claude Nicaise, M.D., and Jeffrey Riley. The appointment of Ernst & Young AG as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 25,865,468 votes in favor.